Calidi Biotherapeutics Operating Income Over Time
| CLDI Stock | 0.73 0.02 2.67% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Calidi Biotherapeutics Performance and Calidi Biotherapeutics Correlation. Is there potential for Biotechnology market expansion? Will Calidi introduce new products? Factors like these will boost the valuation of Calidi Biotherapeutics. Projected growth potential of Calidi fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Calidi Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Calidi's accounting equity. The concept of intrinsic value - what Calidi Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Calidi Biotherapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Calidi Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Calidi Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Calidi Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Calidi Biotherapeutics and related stocks such as Clearmind Medicine Common, Can Fite Biopharma, and Kazia Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CMND | (33.2 K) | (33.2 K) | (33.2 K) | (33.2 K) | (46.9 K) | (24.2 K) | (6.5 K) | (254.5 K) | (105.3 K) | (233.2 K) | (3.6 M) | (9 M) | (8.7 M) | (8 M) | (7.9 M) | (7.1 M) | (6.8 M) |
| CANF | (3.8 M) | (4.8 M) | (6 M) | (9 M) | (7.1 M) | (6.4 M) | (8.6 M) | (7.4 M) | (5.4 M) | (12 M) | (14.1 M) | (12.8 M) | (10.1 M) | (8.2 M) | (8.1 M) | (7.3 M) | (7.7 M) |
| KZIA | (18.1 M) | (9.7 M) | (2 M) | (6.4 M) | (8.1 M) | (12.8 M) | (10.9 M) | (12.5 M) | (8.4 M) | (12.2 M) | (6.4 M) | (25.4 M) | (24.1 M) | (28.5 M) | (14.2 M) | (16.3 M) | (17.2 M) |
| CNSP | (516.3 K) | (516.3 K) | (516.3 K) | (516.3 K) | (516.3 K) | (516.3 K) | (516.3 K) | (516.3 K) | (881.8 K) | (3.8 M) | (9.5 M) | (14.5 M) | (14.9 M) | (18.9 M) | (14.9 M) | (13.4 M) | (14.1 M) |
| SXTP | (418.1 K) | (418.1 K) | (418.1 K) | (418.1 K) | (418.1 K) | (418.1 K) | (418.1 K) | (418.1 K) | (418.1 K) | (418.1 K) | (418.1 K) | (1.1 M) | (1.8 M) | (5.2 M) | (9.7 M) | (8.7 M) | (8.3 M) |
| XBIO | (6.3 M) | (6.3 M) | (6.3 M) | (8.6 M) | (12.9 M) | (9.8 M) | (47.4 M) | (3.6 M) | (7.3 M) | (12.9 M) | (13.9 M) | (5.7 M) | (6.7 M) | (4.5 M) | (4.2 M) | (4.8 M) | (5.1 M) |
| SNGX | (1.3 M) | (3 M) | (4.7 M) | (7.2 M) | (10.8 M) | (7.1 M) | (5.7 M) | (7.6 M) | (9.1 M) | (10.5 M) | (18.6 M) | (13.1 M) | (14.2 M) | (7.7 M) | (9.4 M) | (8.5 M) | (8.9 M) |
Calidi Biotherapeutics and related stocks such as Clearmind Medicine Common, Can Fite Biopharma, and Kazia Therapeutics Operating Income description
Operating Income is the amount of profit realized from Calidi Biotherapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Calidi Biotherapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Calidi Biotherapeutics | CLDI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 4475 Executive Drive, |
| Exchange | NYSE MKT Exchange |
null 0.73
Check out Calidi Biotherapeutics Performance and Calidi Biotherapeutics Correlation. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Calidi Biotherapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.